Drug Trial Radar · NCT06062420
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
316
Actual
Start
Nov 14, 2023
Primary completion
Sep 10, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- iTeos Therapeutics
- First posted
- Oct 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).
Conditions
- Neoplasms, Head and Neck
Interventions
DostarlimabDrug
Dostarlimab will be administered.
BelrestotugDrug
Belrestotug will be administered.
NelistotugDrug
Nelistotug will be administered.
RemzistotugDrug
Remzistotug will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Objective Response Rate (ORR) compared between Sub studies and Dostarlimab monotherapyTime frame: Up to approximately 24 months
Locations
108 sites in 20 countries. Site status is shown where the registry gives one.
GSK Investigational Site
New Haven, Connecticut
GSK Investigational Site
Iowa City, Iowa
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Columbus, Ohio
GSK Investigational Site
Milwaukee, Wisconsin
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Capital Federal, Argentina
GSK Investigational Site
Ciudad Autonoma de Bueno, Argentina
GSK Investigational Site
Córdoba, Argentina
GSK Investigational Site
Florida, Argentina
GSK Investigational Site
Mendoza, Argentina
GSK Investigational Site
San Juan, Argentina
GSK Investigational Site
Santa Fe, Argentina
GSK Investigational Site
Santo André, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Herlev, Denmark
GSK Investigational Site
Turku, Finland
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Caen, France
GSK Investigational Site
Marseille, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Rouen, France
GSK Investigational Site
Villejuif, France
GSK Investigational Site
Aachen, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Giessen, Germany
GSK Investigational Site
Hamburg, Germany
GSK Investigational Site
Regensburg, Germany
GSK Investigational Site
Ulm, Germany
GSK Investigational Site
Frankfurt am Main, Hesse, Germany
GSK Investigational Site
Essen, North Rhine-Westphalia, Germany
GSK Investigational Site
Haidari - Athens, Greece
GSK Investigational Site
Marousi, Greece
GSK Investigational Site
Panórama, Central Macedonia, Greece
Showing 40 of 108 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.